Phase I Chinese PK

An Open Label, Phase I, Rising Multiple Dose, Single Centre Study to Determine the PK and Tolerability of ZD6474 at Different Dose Levels in Chinese Patients With Solid Malignancy Tumor

An open, phase 1 to assess the PK of rising doses of ZD6474 when administered daily in Chinese patients with advanced solid malignant tumors.

Inclusion Criteria:

• histological and/or cytological confirmation of a malignant solid tumor
• refractory to standard therapies or for which no appropriate therapies exist
• WHO performance status 0-2

Exclusion Criteria:

• patients with brain tumors or symptomatic cerebral metastases
• systemic anticancer therapy within the last 4 weeks